Description
The 63D3.rMAb is a recombinant monoclonal antibody that specifically recognizes human CD14 which is also known as Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein, or LPS Receptor (LPS-R). CD14 is expressed as an ~55 kDa glycophosphatidylinositol (GPI)-linked cell surface glycoprotein. CD14 is highly expressed on most mature monocytes and macrophages, and at lower levels on neutrophils. CD14 is also expressed on some dendritic cells (DC) and Langerhans cells. CD14 binds to bacterial cell wall components including lipopolysaccharide (LPS) bound to lipopolysaccharide-binding protein (LBP). CD14 serves as a co-receptor for certain signaling Toll-like receptors (TLRs) for the cellular detection and response to LPS as well as other pathogen-associated molecular patterns (PAMPs). Ligand-bound CD14 plays a role in stimulating various myeloid cells to produce pro-inflammatory cytokines and mediators and to upregulate the expression of cell surface adhesion molecules. Soluble forms of CD14 (sCD14) are reportedly released by cells into the blood or other bodily fluids. Soluble CD14 can regulate cellular responses to LPS and confer LPS-responsiveness to cells that do not ordinarily express CD14.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. CF™ is a trademark of Biotium, Inc.
11. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
